Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $24.2857.

A number of equities research analysts have recently commented on the company. Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target for the company in a report on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. BTIG Research restated a “buy” rating and issued a $15.00 price objective on shares of Tvardi Therapeutics in a research report on Tuesday. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD opened at $3.80 on Friday. The company’s fifty day moving average price is $3.10 and its 200 day moving average price is $3.53. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65. The company has a market capitalization of $35.64 million, a PE ratio of -1.23 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). On average, equities analysts expect that Tvardi Therapeutics will post -2.39 EPS for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC purchased a new position in Tvardi Therapeutics in the 2nd quarter valued at about $2,617,000. JPMorgan Chase & Co. purchased a new stake in Tvardi Therapeutics during the 2nd quarter worth approximately $39,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics during the 2nd quarter worth approximately $92,000. Marshall Wace LLP acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.